X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA PFIZER AJANTA PHARMA/
PFIZER
 
P/E (TTM) x 24.4 31.3 78.1% View Chart
P/BV x 10.1 5.0 202.4% View Chart
Dividend Yield % 0.6 0.7 91.5%  

Financials

 AJANTA PHARMA   PFIZER
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
PFIZER
Mar-16
AJANTA PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,7202,724 63.1%   
Low Rs1,1031,611 68.5%   
Sales per share (Unadj.) Rs194.6440.9 44.1%  
Earnings per share (Unadj.) Rs45.248.7 92.9%  
Cash flow per share (Unadj.) Rs50.375.8 66.4%  
Dividends per share (Unadj.) Rs8.0015.00 53.3%  
Dividend yield (eoy) %0.60.7 81.9%  
Book value per share (Unadj.) Rs132.0462.9 28.5%  
Shares outstanding (eoy) m88.7745.75 194.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.34.9 147.5%   
Avg P/E ratio x31.244.5 70.1%  
P/CF ratio (eoy) x28.128.6 98.1%  
Price / Book Value ratio x10.74.7 228.3%  
Dividend payout %17.730.8 57.4%   
Avg Mkt Cap Rs m125,29999,163 126.4%   
No. of employees `000NA2.9 0.0%   
Total wages/salary Rs m2,5702,758 93.2%   
Avg. sales/employee Rs ThNM6,981.7-  
Avg. wages/employee Rs ThNM954.5-  
Avg. net profit/employee Rs ThNM771.1-  
INCOME DATA
Net Sales Rs m17,27520,170 85.6%  
Other income Rs m166857 19.4%   
Total revenues Rs m17,44221,028 82.9%   
Gross profit Rs m5,8074,310 134.7%  
Depreciation Rs m4511,239 36.4%   
Interest Rs m495 940.4%   
Profit before tax Rs m5,4743,923 139.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m099 0.0%   
Tax Rs m1,4601,794 81.4%   
Profit after tax Rs m4,0142,228 180.2%  
Gross profit margin %33.621.4 157.3%  
Effective tax rate %26.745.7 58.3%   
Net profit margin %23.211.0 210.4%  
BALANCE SHEET DATA
Current assets Rs m7,63916,299 46.9%   
Current liabilities Rs m2,7157,594 35.7%   
Net working cap to sales %28.543.2 66.0%  
Current ratio x2.82.1 131.1%  
Inventory Days Days4365 66.2%  
Debtors Days Days7926 305.5%  
Net fixed assets Rs m6,9148,622 80.2%   
Share capital Rs m177458 38.7%   
"Free" reserves Rs m11,44220,722 55.2%   
Net worth Rs m11,72121,180 55.3%   
Long term debt Rs m14925 594.8%   
Total assets Rs m14,81429,137 50.8%  
Interest coverage x112.9755.5 14.9%   
Debt to equity ratio x00 1,074.8%  
Sales to assets ratio x1.20.7 168.5%   
Return on assets %27.47.7 357.9%  
Return on equity %34.210.5 325.6%  
Return on capital %46.519.0 245.0%  
Exports to sales %55.10.1 92,696.5%   
Imports to sales %6.017.5 34.4%   
Exports (fob) Rs m9,52712 79,392.5%   
Imports (cif) Rs m1,0383,526 29.4%   
Fx inflow Rs m10,42252 20,177.7%   
Fx outflow Rs m1,678140 1,198.9%   
Net fx Rs m8,744-88 -9,898.8%   
CASH FLOW
From Operations Rs m3,2643,436 95.0%  
From Investments Rs m-2,093-6,991 29.9%  
From Financial Activity Rs m-1,186-619 191.6%  
Net Cashflow Rs m-15-4,174 0.4%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 1.6 7.5 20.7%  
FIIs % 7.6 4.9 155.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 23.7 71.7%  
Shareholders   20,968 85,207 24.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 20, 2018 09:17 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS